320 - Assessment of Body Weight upon PK of Olorofim in Patients with Invasive Mould Infections

Co-Author(s)

• KC

  Karen Cornelissen, PhD (she/her/hers)

  Senior Director, Early Clinical Development
  F2G
  Manchester, England, United Kingdom

Co-Author(s)

• 

  John H. Rex, MD

  Chief Medical Officer
  F2G, Limited
  WELLESLEY HILLS, MA, United States

Rapid Fire Presenter(s)

• 

  Daniela Zinzi, Infectious Diseases Specialist (she/her/hers)

  Vice President Clinical R&D
  F2G
  Manchester, England, United Kingdom

Co-Author(s)

• HG

  Hal Galbraith, PharmaD

  IQVIA Inc
  Overland Park, Kansas, United States
• HB

  Howard Burt, PBPK Consultant

  Certara UK Ltd (Simcyp Division)
  Sheffield, England, United Kingdom